Overexpression of steroid receptor coactivator-3 in bone cancers: An in vivo immunohistochemical study with tissue microarray

被引:4
|
作者
Luo, Fei [1 ]
Li, Wei [1 ,3 ]
Zhang, Jiqiang [2 ]
Huang, Ke [1 ]
Fu, Jingshu [1 ]
Xie, Zhao [1 ]
机构
[1] Third Mil Med Univ, Southwest Hosp, Dept Orthoped Surg, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Chongqing Key Lab Neurobiol, Dept Neurobiol, Chongqing 400038, Peoples R China
[3] Bengbu Med Coll, Dept Orthoped Surg, Affiliated Hosp, Bengbu 233030, Anhui, Peoples R China
基金
美国国家科学基金会;
关键词
Bone cancer; Steroid; Steroid receptor coactivators; SRC-3; Immunohistochemistry; Tissue microarray; OSTEOSARCOMA CELLS; GENE-EXPRESSION; ER-ALPHA; ESTROGEN; AIB1; BREAST; SRC-3; PROLIFERATION; TUMORS; CARCINOGENESIS;
D O I
10.1016/j.prp.2013.09.008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Bone tissue is steroid-responsive and profoundly regulated by steroids and/or their receptors. Bone cancers (either primary or metastatic) belong to the most dangerous tumors. Previous studies have demonstrated overexpression of steroid receptor coactivator-3 (SRC-3) in many cancers, such as breast cancer, prostate cancer, thyroid cancer, functioning in the regulation of cancer cell proliferation, invasion, and metastasis. However, so far, the expression and function of SRC-3 in bone cancers have not yet been clarified. In this study, nickel-intensified immunohistochemistry was conducted using a commercial tissue microarray (with 94 cases of bone cancer tissue and 10 normal bone tissues), and the 4-scoring system was employed to evaluate the expression levels of SRC-3 immunoreactivity. The results showed that in normal bone tissue, levels of SRC-3 are almost negative (score = 0), the total positivity (score = 1-3) of SRC-3 immunoreactivities in bone cancers was 74.47%. There were no significant differences in gender, status (malignant or benign) or (mean) age (p >0.05). The percentage of positivity was 77.78% in osteogenic tumors, 58.82% in cartilage tumors, 70% in giant cell tumors, 100% in hematopoietic tumors, 77.78% in miscellaneous lesions, and 75% in miscellaneous tumors. Age related differences of SRC-3 immunoreactivities were detected in cartilage tumors and giant cell tumors (p < 0.05). The above results clearly demonstrated a high frequency of overexpression of SRC-3 immunoreactivities in different bone cancers, indicating its potential roles in the prognosis and treatment of these cancers. (C) 2013 Elsevier GmbH. All rights reserved.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 50 条
  • [41] Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation
    Cai, Di
    Shames, David S.
    Raso, Maria Gabriela
    Xie, Yang
    Kim, Young H.
    Pollack, Jonathan R.
    Girard, Luc
    Sullivan, James P.
    Gao, Boning
    Peyton, Michael
    Nanjundan, Meera
    Byers, Lauren
    Heymach, John
    Mills, Gordon
    Gazdar, Adi F.
    Wistuba, Ignacio
    Kodadek, Thomas
    Minna, John D.
    CANCER RESEARCH, 2010, 70 (16) : 6477 - 6485
  • [42] Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers
    Sakaguchi, Hideki
    Fujimoto, Jiro
    Sun, Wen-Shu
    Tamaya, Teruhiko
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2007, 104 (3-5): : 237 - 240
  • [43] Steroid Receptor Coactivator-3 Regulates Glucose Metabolism in Bladder Cancer Cells through Coactivation of Hypoxia Inducible Factor 1 β
    Zhao, Wei
    Chang, Cunjie
    Cui, Yangyan
    Zhao, Xiaozhi
    Yang, Jun
    Shen, Lan
    Zhou, Ji
    Hou, Zhibo
    Zhang, Zhen
    Ye, Changxiao
    Hasenmayer, Donald
    Perkins, Robert
    Huang, Xiaojing
    Yao, Xin
    Yu, Like
    Huang, Ruimin
    Zhang, Dianzheng
    Guo, Hongqian
    Yan, Jun
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (16) : 11219 - 11229
  • [44] Genetic ablation of steroid receptor coactivator-3 promotes PPAR-β-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis
    Zhang, Yanyun
    Xiao, Yichuan
    JOURNAL OF IMMUNOLOGY, 2010, 184
  • [45] Genetic Ablation of Steroid Receptor Coactivator-3 Promotes PPAR-β-Mediated Alternative Activation of Microglia in Experimental Autoimmune Encephalomyelitis
    Xiao, Yichuan
    Xu, Jingwei
    Wang, Shu
    Mao, Chaoming
    Jin, Min
    Ning, Guang
    Xu, Jianming
    Zhang, Yanyun
    GLIA, 2010, 58 (08) : 932 - 942
  • [46] Short Hairpin RNAs (shRNA) Against Steroid Receptor Coactivator-3/Amplified in Breast Cancer 1 (SRC-3) and Steroid Receptor Coactivator-1 (SRC-1) as Breast Cancer Therapeutic Agents
    Lonard, David M.
    Rao, Donald
    Nemunaitis, John J.
    Senzer, Neil N.
    O'Malley, Bert W.
    MOLECULAR THERAPY, 2013, 21 : S176 - S177
  • [47] Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis
    Kuang, SQ
    Liao, L
    Wang, S
    Medina, D
    O'Malley, BW
    Xu, JM
    CANCER RESEARCH, 2005, 65 (17) : 7993 - 8002
  • [48] Morphologic and immunohistochemical features of triple negative breast cancers: a tissue-microarray study
    Lobrano, R.
    Paliogiannis, P.
    Piras, M. A.
    Marras, V.
    Fedeli, M. A.
    Fara, A.
    Cossu, A.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S191 - S191
  • [49] Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells
    Yoshida, H
    Liu, JS
    Samuel, S
    Cheng, WJ
    Rosen, D
    Naora, H
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2005, 245 (1-2) : 77 - 85
  • [50] Steroid receptor coactivator-3 is required for progesterone receptor trans-activation of target genes in response to gonadotropin-releasing hormone treatment of pituitary cells
    An, Beum-Soo
    Selva, David M.
    Hammond, Geoffrey L.
    Rivero-Muller, Adolfo
    Rahman, Nafis
    Leung, Peter C. K.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (30) : 20817 - 20824